334 related articles for article (PubMed ID: 28532567)
21. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Andersson NW; Zachariae C; Simonsen AB
Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
[No Abstract] [Full Text] [Related]
22. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
[TBL] [Abstract][Full Text] [Related]
23. New drugs and new toxicities: pembrolizumab-induced myocarditis.
Inayat F; Masab M; Gupta S; Ullah W
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
[TBL] [Abstract][Full Text] [Related]
24. Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.
Kanekura T; Arimura A; Kirishima M; Tanimoto A
J Dermatol; 2019 Dec; 46(12):1202-1204. PubMed ID: 31599020
[TBL] [Abstract][Full Text] [Related]
25. Hyponatremia in a Patient With Cancer.
Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
[No Abstract] [Full Text] [Related]
26. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
[TBL] [Abstract][Full Text] [Related]
27. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
28. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
29. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
30. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
31. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
32. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
Yonenobu Y; Ishijima M; Toyooka K; Fujimura H
Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688
[TBL] [Abstract][Full Text] [Related]
33. Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Osman GA; Marra A; Iacono D; Giannelli V; Ricciardi S; Remotti D; Vecchione A; Ricci A; Palange P; Migliorino MR
Anticancer Drugs; 2019 Aug; 30(7):e0764. PubMed ID: 30950836
[TBL] [Abstract][Full Text] [Related]
34. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
Facchinetti F; Majori M; Sabato M; Gnetti L; Tiseo M
Immunotherapy; 2019 Feb; 11(3):161-166. PubMed ID: 30730279
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
36. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
[No Abstract] [Full Text] [Related]
37. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
38. Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.
Yaga M; Shiroyama T; Hirata H; Oya K; Takeda Y; Kumanogoh A
Clin Lung Cancer; 2022 Mar; 23(2):e116-e117. PubMed ID: 34980563
[No Abstract] [Full Text] [Related]
39. Case of post-progression prolongation of survival after cessation of pembrolizumab in advanced non-small-cell lung cancer.
Liu J; Wong K; Patanjali N; Boyer M; Kao S
Intern Med J; 2020 Jun; 50(6):771-773. PubMed ID: 32537926
[No Abstract] [Full Text] [Related]
40. Pembrolizumab induced toxic epidermal necrolysis.
Kumar R; Bhandari S
Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]